Telomir Pharmaceuticals announces in vitro data on Telomir-1

Telomir Pharmaceuticals (TELO) announced new in vitro results that expand understanding of its lead drug candidate, Telomir-1. In studies conducted by Eurofins Discovery, Telomir-1 was shown to potently inhibit UTX, an enzyme that acts like an “eraser” of chemical tags on DNA packaging proteins. These tags, known as DNA methylation and histone marks, are part of the body’s system for deciding which genes are turned on or off – much like switches on a circuit board. When UTX activity is abnormal, it can silence protective genes and activate harmful ones, a pattern commonly seen in cancer, autoimmune disease, and neurodegeneration. Beyond cancer, UTX has also been linked to the biology of aging itself. Studies show that UTX influences stem cell renewal, reprogramming, and differentiation – meaning it helps control how effectively tissues can repair themselves as we age. UTX works in close connection with DNA methylation, and when this coordination breaks down it can lead to epigenetic drift – the gradual loss of proper gene regulation that occurs with aging and underlies many chronic diseases, including cancer, autism spectrum disorder, neurodegeneration, and metabolic dysfunction. Because UTX has long been considered undruggable, Telomir-1’s ability to block it is a major step forward. By doing so, Telomir-1 may help reset faulty DNA methylation patterns, restore proper gene control, support stem cell function, and counteract age-related epigenetic drift – reawakening the body’s natural defenses against both disease and decline. “Everything from cancer to aging to autism has been linked to faulty DNA methylation. Telomir-1 is capable to jointly reset several of those methylation patterns – which could make it one of the first drugs to address the root biology driving so many diseases,” said Erez Aminov, CEO of Telomir.